Nintedanib Eg

Nintedanib, the active ingredient in Nintedanib Eg, is a tyrosine kinase inhibitor presented as an oral capsule for oral use. It is indicated for certain fibrotic lung conditions and for use in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib acts on pathways that drive fibrosis and tumor angiogenesis, making it useful in several serious respiratory and oncologic conditions. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other anticancer agents.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Vomiting: occasional episodes, usually self‑limiting. - Decreased appetite: reduced desire to eat. - Liver enzyme elevation: mild increases in ALT/AST. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Gastrointestinal perforation: rare but potentially life‑threatening. - Cardiovascular events: such as myocardial infarction or stroke. - Severe bleeding: especially in patients on anticoagulants. - Interstitial lung disease exacerbation: worsening of underlying lung disease. - Allergic reactions: including rash, urticaria, or anaphylaxis.

Before initiating therapy, clinicians should assess baseline organ function and review concomitant medications. - Liver function monitoring: obtain baseline ALT/AST and repeat periodically. - Gastrointestinal assessment: monitor for persistent diarrhoea or abdominal pain. - Bleeding risk: evaluate patients on anticoagulants or with a history of bleeding. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Storage: Store below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels. - P-glycoprotein inhibitors (e.g., verapamil): could increase systemic exposure. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy by lowering drug concentrations.